Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Amgen (AMGN) shares have recently underperformed, falling 3.6% over the past month, despite the biotech giant's consistent history of beating earnings estimates and projections for robust revenue growth of 17-18% for the current fiscal year. While current fiscal year EPS is estimated to grow 4.4%, mixed recent earnings estimate revisions have led to a Zacks Rank #3 (Hold), suggesting the stock is expected to perform in line with the broader market in the near term, trading at a valuation on par with its peers.

Analysis

Amgen (AMGN) presents a mixed fundamental picture, contributing to its recent stock underperformance of -3.6% over the past month, which trails both the S&P 500 composite's +3.3% gain and its industry's -2.2% loss. On the positive side, the company has a strong track record of beating consensus EPS estimates for the last four quarters and is projected to deliver robust top-line growth, with consensus sales estimates pointing to an 18.3% year-over-year increase for the current quarter and 17% for the full fiscal year. However, this strong revenue growth does not fully translate to near-term profitability, as current quarter EPS is forecast to decline by 2.8% to $4.86. Furthermore, analyst earnings estimate revisions over the last 30 days have been largely stagnant and slightly negative for key periods, moving -0.1% for the current quarter and -0.2% for the next fiscal year. This lack of positive earnings momentum, a valuation grade of 'C' indicating it is trading at par with peers, and a significant projected slowdown in revenue growth to 3.1% next fiscal year, collectively support its Zacks Rank #3 (Hold), suggesting the stock may perform in line with the broader market.

Key Decisions for Investors

• Given the stock's recent underperformance and neutral Zacks #3 (Hold) rating, investors may consider holding current positions, as the analysis suggests performance in line with the broader market in the near term.
• Investors should closely monitor the significant projected deceleration in revenue growth from 17% in the current fiscal year to 3.1% in the next, as this is a primary forward-looking risk factor.
• Scrutinize the next earnings report for any improvement in the conversion of strong revenue growth into bottom-line profit, as the current quarter's projected 2.8% year-over-year EPS decline is a key concern.
• With valuation at par with peers, there is no clear valuation-based catalyst, so any new positions could be predicated on a positive shift in analyst earnings revisions or a price dislocation unsupported by fundamentals.